H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Kymera Therapeutics to $60 from $46 and keeps a Buy rating on the shares. The analyst says positive biomarker trends can be the reason behind the KT-474 trial expansion. The firm views Sanofi’s decision to expand the trial as de-risking for KT-474 program, and therefore increased its probability of sucess for KT-474 from 35% to 45%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
- KYMR Upcoming Earnings Report: What to Expect?
- Kymera Therapeutics director sells $17.3M in common stock
- Kymera Therapeutics price target raised to $36 from $31 at B. Riley